casagrande john (28 Ergebnisse)

paperback. Zustand: Fair.

Brossura. Zustand: new. Pomezia, 2022; br., pp. 290.(Mondo Incantato). Tempi bui a Pupazzolandia: l'Ego, il re della menzogna, spalleggiato dai suoi scagnozzi, Paura, i gemelli Delusione e Rassegnazione, Tristezza e la terribile Rabbia, sta devastando il pianeta Terra e un'ombra è così calata sul Paese dei Pupazzi, precipitandolo nella tristezza e nell'aridità. Burro un orsacchiotto di pezza, guarda la vita attorno a lui spegnersi ogni giorno di più, ma il rinvenimento di un antico libro tra le macerie del mondo che resta, cambierà il suo destino e dei suoi amici, eleggendoli a paladini della pace del coraggio e della giustizia. L'Ego va sconfitto, ma non saranno soli in questa missione: l'Universo vuole che sia un bambino ad aiutarli, il piccolo Ravih, lo sguardo innocente e disincantato di un fanciullo che non conosce la malizia, l'inganno, il pregiudizio, ma che si apre all'avventura e alla vita con entusiasmo e coraggio. Una favola ispirata in un istante di grazia, scritta per i bambini ma destinata ad accarezzare il cuore degli adulti, riallacciando un contatto e innescando una guarigione con il bambino interiore che ognuno di noi porta dentro. Libro.

paperback. Zustand: New. In shrink wrap. Looks like an interesting title!

Hardcover. Zustand: Fine. Zustand des Schutzumschlags: Fine. 352 p. : illustrated in color ; Dewey: 659.1 ; OCLC: 682927275 ; ISBN: 1887165428; 9781887165426 ; OCLC: 682927275 ; magenta cloth in photographic dustjacket ; photos, Hans Gissinger, Anderson Hopkins, Sia Aryal, Kolea Baker, Jorg Badura, Noel Barnhurst, Robin Bartholick, Frits Berends, HOward Berman, Jay Blakesberg, Barbara Bowman, David Allan Brandt, Berman Bronstein, Neal Brown, Angela Cappetta, Bob Carey, Magdalena Caris, Reggie Casagrande, Greg Ceo, Lance Clayton, Tom Collicott, Jim Cooper, Ann Elliott Cutting, Harry Se Zitter, Thierry Des Fontaines, Phillip Dixon, Jeffrey Engelstad, Dwight Eschliman, Georg Fischer, Jim Flynn, Bill Geddes, Leo Gong, Jennifer Goodin, Robb Aaron Gordon, Greg Gorman, Jeffrey Green, Joe Greene, Xavier Guardans, Maggie Hallahan, Jensen Hande, Simon Harsent, Laura Healy Engelstad, Sean Hennessy, Ruedi Hofmann, John Holt, Walter Iooss,Heather Julian, Philip Kaake, Henrik Kam, Pat Kane, Tom Kates, Jim Kemper, Parish Kohanim, Cheryl Koralik, Hugh Kretschmer, Mona Kuhn, Dah Len, Jana Leon, Steven Lippman, Peter S Lopez, Graham MacIndoe, Vasily Mallas, Andrea Marouk, Norman Maslov, Lise Metzger, Peter Read Miller, Heather Monahan, David Moore, Paul Moore, Ted Morrison, RJ Muna, Curtis Myers, Clare O'Dea, John Offenbach, Craig Cameron Olsen, Rosanne Olson, Greg Pease, David Peterson, Plamen Petkov, Lyn Porterfield, Alan Powdrill, Michael Prince, Ken Probst, Richard Radstone, Wayne Rainey, Stuart Redler, David Sacks, James Salzano, Vicki Sander, Charles Schiller, Martin Schoeller, Wilhelm Scholz, Bob Scott, Richard Seagraves, Nancy Shanahan, Frank Short, Tomek Sikora, Nicole Sloan, Maureen Smith, Wayne Smith, Daryl Solomon, Martel Stockland, KAte Swan, Trish Swords, Leen Thisse, Mitch TObias, Eric Tucker, Kevin Twomey, Victor J Volta, Sacha Waldman, Elizabeth Watt, Mark Weiss, Tiffant Whitford, Steve Whittaker, Everard Williams Jr., Bret Wills, Pierre Winther, Mitchell Wood, Peter Zander, Brian Hagiwara, and Michael Zeppetello ; large volume ; FINE/FINE. Book.

Zustand: New. In.

Taschenbuch. Zustand: Neu. Biomedical Informatics for Cancer Research | Michael F. Ochs (u. a.) | Taschenbuch | xviii | Englisch | 2014 | Springer | EAN 9781489984517 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Zustand: New. In.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - view, showing that multiple molecular pathways must be affected for cancer to develop, but with different specific proteins in each pathway mutated or differentially expressed in a given tumor (The Cancer Genome Atlas Research Network 2008; Parsons et al. 2008). Different studies demonstrated that while widespread mutations exist in cancer, not all mutations drive cancer development (Lin et al. 2007). This suggests a need to target only a deleterious subset of aberrant proteins, since any tre- ment must aim to improve health to justify its potential side effects. Treatment for cancer must become highly individualized, focusing on the specific aberrant driver proteins in an individual. This drives a need for informatics in cancer far beyond the need in other diseases. For instance, routine treatment with statins has become widespread for minimizing heart disease, with most patients responding to standard doses (Wilt et al. 2004). In contrast, standard treatment for cancer must become tailored to the molecular phenotype of an individual tumor, with each patient receiving a different combination of therapeutics aimed at the specific aberrant proteins driving the cancer. Tracking the aberrations that drive cancers, identifying biomarkers unique to each individual for molecular-level di- nosis and treatment response, monitoring adverse events and complex dosing schedules, and providing annotated molecular data for ongoing research to improve treatments comprise a major biomedical informatics need.

Zustand: Sehr gut. Zustand: Sehr gut | Seiten: 372 | Sprache: Englisch | Produktart: Bücher | view, showing that multiple molecular pathways must be affected for cancer to develop, but with different specific proteins in each pathway mutated or differentially expressed in a given tumor (The Cancer Genome Atlas Research Network 2008; Parsons et al. 2008). Different studies demonstrated that while widespread mutations exist in cancer, not all mutations drive cancer development (Lin et al. 2007). This suggests a need to target only a deleterious subset of aberrant proteins, since any tre- ment must aim to improve health to justify its potential side effects. Treatment for cancer must become highly individualized, focusing on the specific aberrant driver proteins in an individual. This drives a need for informatics in cancer far beyond the need in other diseases. For instance, routine treatment with statins has become widespread for minimizing heart disease, with most patients responding to standard doses (Wilt et al. 2004). In contrast, standard treatment for cancer must become tailored to the molecular phenotype of an individual tumor, with each patient receiving a different combination of therapeutics aimed at the specific aberrant proteins driving the cancer. Tracking the aberrations that drive cancers, identifying biomarkers unique to each individual for molecular-level di- nosis and treatment response, monitoring adverse events and complex dosing schedules, and providing annotated molecular data for ongoing research to improve treatments comprise a major biomedical informatics need.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - view, showing that multiple molecular pathways must be affected for cancer to develop, but with different specific proteins in each pathway mutated or differentially expressed in a given tumor (The Cancer Genome Atlas Research Network 2008; Parsons et al. 2008). Different studies demonstrated that while widespread mutations exist in cancer, not all mutations drive cancer development (Lin et al. 2007). This suggests a need to target only a deleterious subset of aberrant proteins, since any tre- ment must aim to improve health to justify its potential side effects. Treatment for cancer must become highly individualized, focusing on the specific aberrant driver proteins in an individual. This drives a need for informatics in cancer far beyond the need in other diseases. For instance, routine treatment with statins has become widespread for minimizing heart disease, with most patients responding to standard doses (Wilt et al. 2004). In contrast, standard treatment for cancer must become tailored to the molecular phenotype of an individual tumor, with each patient receiving a different combination of therapeutics aimed at the specific aberrant proteins driving the cancer. Tracking the aberrations that drive cancers, identifying biomarkers unique to each individual for molecular-level di- nosis and treatment response, monitoring adverse events and complex dosing schedules, and providing annotated molecular data for ongoing research to improve treatments comprise a major biomedical informatics need.

Zustand: New. pp. 374.

Hardcover. Zustand: Brand New. 1st edition. 354 pages. 9.25x6.00x0.75 inches. In Stock.

Paperback. Zustand: New.

Paperback. Zustand: New.

Hardcover. Zustand: New. First Edition, First Printing. SIGNED - Nazraeli Press, 2023. 4 Hardcover Volumes in Slipcase (and plain white shipping box). First Edition & First Printing. #45, Kimono by Eikoh Hosoe; #46, Toer by Susan Zadeh; #47, Paperworks by Benedetta Casagrande; #48, Italian Cars by John Divola. Each title is limited to 500 numbered copies, and includes a removable, signed, original print measuring approximately 5x7 inches. Each book is numbered with 3 prints being individually HAND-SIGNED by the artist and the Hosoe print stamp-signed. BOOK CONDITION: Fine/As New: The Set. SIGNED. Signed.

Paperback. Zustand: New.

Paperback. Zustand: New.

Zustand: new. Questo è un articolo print on demand.

Zustand: new. Questo è un articolo print on demand.

Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -view, showing that multiple molecular pathways must be affected for cancer to develop, but with different specific proteins in each pathway mutated or differentially expressed in a given tumor (The Cancer Genome Atlas Research Network 2008; Parsons et al. 2008). Different studies demonstrated that while widespread mutations exist in cancer, not all mutations drive cancer development (Lin et al. 2007). This suggests a need to target only a deleterious subset of aberrant proteins, since any tre- ment must aim to improve health to justify its potential side effects. Treatment for cancer must become highly individualized, focusing on the specific aberrant driver proteins in an individual. This drives a need for informatics in cancer far beyond the need in other diseases. For instance, routine treatment with statins has become widespread for minimizing heart disease, with most patients responding to standard doses (Wilt et al. 2004). In contrast, standard treatment for cancer must become tailored to the molecular phenotype of an individual tumor, with each patient receiving a different combination of therapeutics aimed at the specific aberrant proteins driving the cancer. Tracking the aberrations that drive cancers, identifying biomarkers unique to each individual for molecular-level di- nosis and treatment response, monitoring adverse events and complex dosing schedules, and providing annotated molecular data for ongoing research to improve treatments comprise a major biomedical informatics need. 372 pp. Englisch.

Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. view, showing that multiple molecular pathways must be affected for cancer to develop, but with different specific proteins in each pathway mutated or differentially expressed in a given tumor (The Cancer Genome Atlas Research Network 2008 Parsons et al. 2.

Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -view, showing that multiple molecular pathways must be affected for cancer to develop, but with different specific proteins in each pathway mutated or differentially expressed in a given tumor (The Cancer Genome Atlas Research Network 2008; Parsons et al. 2008). Different studies demonstrated that while widespread mutations exist in cancer, not all mutations drive cancer development (Lin et al. 2007). This suggests a need to target only a deleterious subset of aberrant proteins, since any tre- ment must aim to improve health to justify its potential side effects. Treatment for cancer must become highly individualized, focusing on the specific aberrant driver proteins in an individual. This drives a need for informatics in cancer far beyond the need in other diseases. For instance, routine treatment with statins has become widespread for minimizing heart disease, with most patients responding to standard doses (Wilt et al. 2004). In contrast, standard treatment for cancer must become tailored to the molecular phenotype of an individual tumor, with each patient receiving a different combination of therapeutics aimed at the specific aberrant proteins driving the cancer. Tracking the aberrations that drive cancers, identifying biomarkers unique to each individual for molecular-level di- nosis and treatment response, monitoring adverse events and complex dosing schedules, and providing annotated molecular data for ongoing research to improve treatments comprise a major biomedical informatics need.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 372 pp. Englisch.

Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. view, showing that multiple molecular pathways must be affected for cancer to develop, but with different specific proteins in each pathway mutated or differentially expressed in a given tumor (The Cancer Genome Atlas Research Network 2008 Parsons et al. 2.

Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -view, showing that multiple molecular pathways must be affected for cancer to develop, but with different specific proteins in each pathway mutated or differentially expressed in a given tumor (The Cancer Genome Atlas Research Network 2008; Parsons et al. 2008). Different studies demonstrated that while widespread mutations exist in cancer, not all mutations drive cancer development (Lin et al. 2007). This suggests a need to target only a deleterious subset of aberrant proteins, since any tre- ment must aim to improve health to justify its potential side effects. Treatment for cancer must become highly individualized, focusing on the specific aberrant driver proteins in an individual. This drives a need for informatics in cancer far beyond the need in other diseases. For instance, routine treatment with statins has become widespread for minimizing heart disease, with most patients responding to standard doses (Wilt et al. 2004). In contrast, standard treatment for cancer must become tailored to the molecular phenotype of an individual tumor, with each patient receiving a different combination of therapeutics aimed at the specific aberrant proteins driving the cancer. Tracking the aberrations that drive cancers, identifying biomarkers unique to each individual for molecular-level di- nosis and treatment response, monitoring adverse events and complex dosing schedules, and providing annotated molecular data for ongoing research to improve treatments comprise a major biomedical informatics need. 372 pp. Englisch.

Buch. Zustand: Neu. Biomedical Informatics for Cancer Research | Michael F. Ochs (u. a.) | Buch | xviii | Englisch | 2010 | Springer | EAN 9781441957122 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.

Buch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -view, showing that multiple molecular pathways must be affected for cancer to develop, but with different specific proteins in each pathway mutated or differentially expressed in a given tumor (The Cancer Genome Atlas Research Network 2008; Parsons et al. 2008). Different studies demonstrated that while widespread mutations exist in cancer, not all mutations drive cancer development (Lin et al. 2007). This suggests a need to target only a deleterious subset of aberrant proteins, since any tre- ment must aim to improve health to justify its potential side effects. Treatment for cancer must become highly individualized, focusing on the specific aberrant driver proteins in an individual. This drives a need for informatics in cancer far beyond the need in other diseases. For instance, routine treatment with statins has become widespread for minimizing heart disease, with most patients responding to standard doses (Wilt et al. 2004). In contrast, standard treatment for cancer must become tailored to the molecular phenotype of an individual tumor, with each patient receiving a different combination of therapeutics aimed at the specific aberrant proteins driving the cancer. Tracking the aberrations that drive cancers, identifying biomarkers unique to each individual for molecular-level di- nosis and treatment response, monitoring adverse events and complex dosing schedules, and providing annotated molecular data for ongoing research to improve treatments comprise a major biomedical informatics need.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 372 pp. Englisch.

Zustand: New. Print on Demand pp. 374 57 Illus. (37 Col.).

Zustand: New. PRINT ON DEMAND pp. 374.